Current progress in antibacterial agents for carbapenem-resistant enterobacterales. [PDF]
Xu W +10 more
europepmc +1 more source
From bugs to bots: learning infectious diseases in the AI era. [PDF]
Rodriguez-Nava G.
europepmc +1 more source
Targeting carbapenem-resistant and hypervirulent Klebsiella pneumoniae: in vitro evaluation of cefepime/zidebactam, aztreonam/avibactam, imipenem/relebactam, and meropenem/vaborbactam. [PDF]
Li Y, Li Y, Jia X, Mao H, Li D, Zhang J.
europepmc +1 more source
Antimicrobial Susceptibility of <i>Pseudomonas aeruginosa</i> from Elderly Patients in Intensive Care Units of United States Medical Centers (2021-2025). [PDF]
Sader HS +4 more
europepmc +1 more source
TDM-guided meropenem/vaborbactam-based therapy for successful treatment of intra-abdominal and bloodstream infection caused by KPC-producing ceftazidime/avibactam-resistant Klebsiella pneumoniae in a paediatric liver transplant recipient. [PDF]
Mulé G +8 more
europepmc +1 more source
Classification and applicability of new beta-lactamase inhibitors. [PDF]
Cercenado E, Candel FJ.
europepmc +1 more source
The shift from "MIC-Only" back to carbapenemase testing among carbapenem-resistant Enterobacterales: what clinical laboratories need to know about updated CLSI guidance. [PDF]
Simner PJ.
europepmc +1 more source
Emergence of Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae with Penicillin-Binding Protein 3 Insertions, Taiwan, 2021. [PDF]
Long T +6 more
europepmc +1 more source

